Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer
2016 · Annals of Oncology · 59 citations
https://doi.org/10.1093/annonc/mdw132
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
22
Papers
812
Citations
14
h-index
15
i10-index
Daniel Grun is an academic researcher from Frederick National Laboratory for Cancer Research. The author has contributed to research in topics: Hippo pathway signaling and YAP/TAZ & Cancer Cells and Metastasis & Epigenetics and DNA Methylation. The author has an h-index of 14, co-authored 19 publications.
ORCID: 0000-0003-4261-7765https://doi.org/10.1093/annonc/mdw132
https://doi.org/10.3389/fimmu.2024.1380065
Click to start Chat